Solitary Skeletal Osteosarcoma Recurrence. Findings From the Cooperative Osteosarcoma Study Group

被引:23
作者
Franke, Markus [2 ]
Hardes, Jendrik [3 ]
Helmke, Knut [4 ]
Jundt, Gernot [5 ]
Juergens, Heribert [6 ]
Kempf-Bielack, Beate
Kevric, Matthias
Tunn, Per-Ulf [7 ]
Werner, Mathias [8 ]
Bielack, Stefan [1 ]
机构
[1] Olga Hosp, Cooperat Osteosarkomstudiengrp COSS, Klinikum Stuttgart, COSS Study Ctr, D-70176 Stuttgart, Germany
[2] Olga Hosp, Klinikum Stuttgart, Dept Pediat Surg, Stuttgart, Germany
[3] Univ Hosp Muenster, Dept Gen Orthoped & Tumororthoped, Munster, Germany
[4] Univ Hosp Hamburg Eppendorf, Dept Pediat Radiol, Hamburg, Germany
[5] Univ Spital Basel, Dept Pathol, Basel, Switzerland
[6] Univ Childrens Hosp Muenster, Dept Pediat Hematol & Oncol, Munster, Germany
[7] Charite, Dept Orthoped Oncol, Sarcoma Ctr Berlin Brandenburg, Helios Klinikum Berlin Buch,Acad Teaching Hosp, D-13353 Berlin, Germany
[8] Charite, Dept Pathol, Sarcoma Ctr Berlin Brandenburg, Helios Klinikum Emil von Behring,Acad Teaching Ho, D-13353 Berlin, Germany
关键词
child; osteosarcoma; recurrence; STUDY-GROUP COSS; PROGNOSTIC-FACTORS; BONE METASTASES; NEOADJUVANT; EXPERIENCE; CHEMOTHERAPY; THERAPY; RADIOTHERAPY; EXTREMITIES; ADJUVANT;
D O I
10.1002/pbc.22864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Solitary skeletal osteosarcoma (OS) manifestations distant from the site of the primary tumor rarely arise as only sign of disease recurrence. Methods. This report reviews 38 patients with high-gradecentral OS of the limbs or axial skeleton and initial complete surgical remission (CR) who developed first recurrences as solitary osseous lesions distant from the primary tumor. The Cooperative Osteosarcoma Study Group (COSS) database was used to evaluate patient-, tumor-, and treatment-related variables and outcomes. Results. Thirty-eight patients (27 males and 11 females; 36 limb and 2 axial primaries) developed solitary osseous recurrences a median of 2.1 years (range: 0.5-14.3) from primary diagnosis. Relapses involved axial (24), extremity (10), or craniofacial bones (4). Treatment for recurrence included surgery (28), radiotherapy (10), and chemotherapy (27). After a median follow-up of 1.9 years (range: 0.1-21.2) from first recurrence for all 38 patients and 5.5 years (0.3-21.2) for 16 survivors (10 in continuous second CR), 2- and 5-year overall and event-free survival (EFS) probabilities were 55% and 34% and 34% and 27%, respectively. A long interval to recurrence (> 1.5 years) predicted for better overall (P < 0.001) and EFS (P = 0.005). For 21 patients achieving a second CR, 2- and 5-year overall and EFS probabilities were 81% and 61% and 52% and 49%, respectively, while only 1/17 others survived beyond 5 years (P < 0.001). Survivors (14/16) had also received second-line chemotherapy. Conclusion. First solitary skeletal recurrences of OS should be treated with curative intent. Some presumed bone metastases may represent second primary OSs. Pediatr Blood Cancer 2011;56:771-776. (c) 2010 Wiley-Liss, Inc.
引用
收藏
页码:771 / 776
页数:6
相关论文
共 19 条
[1]   Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma [J].
Aung, L ;
Gorlick, R ;
Healey, JH ;
Ski, WJ ;
Thaler, HT ;
Shorter, NA ;
Huvos, AG ;
Meyers, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :342-348
[2]   Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy - The Rizzoli experience in 52 patients [J].
Bacci, Gaetano ;
Longhi, Alessandra ;
Bertoni, Franco ;
Briccoli, Antonio ;
Versari, Michela ;
Pignotti, Elettra ;
Picci, Piero .
ACTA ORTHOPAEDICA, 2006, 77 (06) :938-943
[3]  
Bielack S, 1999, KLIN PADIATR, V211, P260, DOI 10.1055/s-2008-1043798
[4]   Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up [J].
Bielack, S. ;
Carrle, D. ;
Casali, P. G. .
ANNALS OF ONCOLOGY, 2009, 20 :137-139
[5]   Combined modality treatment for osteosarcoma occurring as a second malignant disease [J].
Bielack, SS ;
Kempf-Bielack, B ;
Heise, U ;
Schwenzer, D ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1164-1174
[6]   Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[7]   Osteosarcoma: The COSS Experience [J].
Bielack, Stefan ;
Juergens, Herbert ;
Jundt, Gernot ;
Kevric, Matthias ;
Kuehne, Thomas ;
Reichardt, Peter ;
Zoubek, Andreas ;
Werner, Mathias ;
Winkelmann, Winfried ;
Kotz, Rainer .
PEDIATRIC AND ADOLESCENT OSTEOSARCOMA, 2009, 152 :289-+
[8]   Synchronous and metachronous skeletal osteosarcomas: The Norwegian Radium Hospital experience [J].
Brandal, Petter ;
Bjerkehagen, Bodil ;
Bruland, Oyvind S. ;
Skjeldal, Sigmund ;
Bogsrud, Trond V. ;
Hall, Kirsten S. .
ACTA ONCOLOGICA, 2009, 48 (08) :1165-1172
[9]   Radiotherapy for local control of osteosarcoma [J].
DeLaney, TF ;
Park, L ;
Goldberg, SI ;
Hug, EB ;
Liebsch, NJ ;
Munzenrider, JE ;
Suit, HD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02) :492-498
[10]   Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival [J].
Ferrari, S ;
Briccoli, A ;
Mercuri, M ;
Bertoni, F ;
Picci, P ;
Tienghi, A ;
Del Prever, AB ;
Fagioli, F ;
Comandone, A ;
Bacci, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :710-715